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Stem cell therapies have shown promise in promoting recovery in stroke but have been limited by poor
cell survival and differentiation. We have developed a hyaluronic acid (HA)-based self-polymerizing
hydrogel that serves as a platform for adhesion of structural motifs and a depot release for growth
factors to promote transplant stem cell survival and differentiation. We took an iterative approach in
optimizing the complex combination of mechanical, biochemical and biological properties of an HA cell
scaffold. First, we optimized stiffness for a minimal reaction of adjacent brain to the transplant. Next
hydrogel crosslinkers sensitive to matrix metalloproteinases (MMP) were incorporated as they promoted
vascularization. Finally, candidate adhesion motifs and growth factors were systemically changed in vitro
using a design of experiment approach to optimize stem cell survival or proliferation. The optimized HA
hydrogel, tested in vivo, promoted survival of encapsulated human neural progenitor cells (iPS-NPCs)
after transplantation into the stroke core and differentially tuned transplanted cell fate through the
promotion of glial, neuronal or immature/progenitor states. This HA hydrogel can be tracked in vivowith
MRI. A hydrogel can serve as a therapeutic adjunct in a stem cell therapy through selective control of
stem cell survival and differentiation in vivo.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Stroke is the leading cause of long-term disability [1]. There are
no therapies that promote recovery in this disease. New strategies
aimed at enhancing post-stroke brain plasticity have utilized tro-
phic factors, stem cell therapies or a combination of the two.
However, their clinical translation has been limited because of the
short half-life and undesirable systemic effects of injected growth
factors [2,3] and poor survival of transplanted cells [4], partly due to
the abrupt withdrawal of adhesive support and the inﬂammatory
environment of the damaged brain [5]. Although there are manycarmichael@mednet.ucla.edu
er Ltd. This is an open access articprotocols to differentiate in vitro stem/progenitor cells to desired
fates, in vivo these protocols are either not possible or fail to
differentiate the cells to the same extent. The lack of a successful
medical therapy that promotes long-term recovery in stroke im-
poses a substantial clinical and economic burden, indicating the
need for a novel therapeutic solution.
Recent advances in tissue engineering have developed inject-
able hydrogels that can serve both as a protective vehicle for cells
and a depot release platform for trophic factors, with distinct
synergistic advantages of both strategies. Cell-loaded hydrogels
provide structural support that not only directly promote the sur-
vival of encapsulated cells [6], but also promote cell inﬁltration
from the surrounding parenchyma [7] and reduce the glial scar and
inﬂammation at the ischemic border [8,9]. Similarly, local drug
delivery from injectable hydrogels can achieve sustained [3,10,11]
or sequential delivery [12] in a time- and space-controlled
manner, while enhancing protein stability, diffusion distance and
in vivo bioactivity [11]. Polymer-based hydrogels are highlyle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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host tissue. For example, a simple alteration of the polymer length,
the crosslinking points and/or the scaffold mesh size can modulate
gel stiffness, nutrient diffusion, and even cell motility [13]. Recent
studies have shown that awide variety of chemical, mechanical and
spatial cues can be incorporated into cellematerial interactions to
ultimately allow for greater control over cell behavior [14].
Hyaluronic acid (HA) gels are appealing choices for cell encap-
sulation in a transplant approach. HA is abundantly found in the
brain, particularly in the endogenous environment for neural pro-
genitor cells (NPCs) [15] and it is both a biocompatible and bio-
resorbable material that allows cells to degrade it as they spread
within the gel [16]. We have previously reported a hyaluronic acid
hydrogel crosslinked in situ via thiol/acrylate Michael type addition
for human induced pluripotent neural precursor (iPS-NPC) culture
in vitro,which demonstrated biocompatibility after transplantation
in vivo [13].
Stroke offers a unique opportunity for a tissue engineering
neural repair therapy. After initial cell death in stroke, the clearance
of debris in the lesion leaves a compartmentalized cavity that can
accept a large volume transplant without further damaging the
surrounding healthy parenchyma [17]. This stroke cavity is situated
directly adjacent to the peri-infarct tissue, the region of the brain
that undergoes the most substantial repair and recovery, meaning
that any therapeutic delivered to the cavity will have direct access
to the tissue target for repair [2]. Although utilizing a hydrogel
material to promote differentiation of transplanted stem cells is a
logical next step, no published study has shown substantial dif-
ferentiation or differential control over post-transplantation cell
fate. We developed a hydrogel material that can control trans-
planted human neural progenitor cell fate in vivo after the injection
through the modulation of adhesive and trophic signals delivered
from the scaffold. We show that the material can be optimized
in vitro to result in either maintenance of the progenitor state or
differentiation towards different central nervous system fates
in vivo. Our ﬁndings mark the ﬁrst time a hydrogel has been engi-
neered to control transplanted human stem/progenitor cell fate
in vivo utilizing in vitro ﬁndings.
2. Materials and methods
2.1. Cell culture
Induced pluripotent stem cells (iPS) were generated from hu-
man ﬁbroblasts and characterized [18] under approved protocols
from the UCLA ESCRO. NPCs were differentiated from iPS through
formation of neural rosettes and maintained in culture [19]. On the
day of transplantation human iPS-NPCs were harvested by TrypLE
treatment (3e5 min; Life Technologies), centrifuged at 300 g for
5 min, re-suspended in maintenance culture medium and kept on
ice. Cell viability throughout transplantation process remained
above 95%e97% as determined by Trypan blue exclusion method.
Animal origin-free products were used for the cell culture.
2.2. Hyaluronic acid modiﬁcation
Hyaluronic acid (60,000 Da, Genzyme, Cambridge, MA) was
functionalized with an acrylate group using a two-step synthesis as
previously described [20]. After dissolving the HA (2.0 g,
5.28 mmol) in water, it was reacted with adipic dihydrazide (ADH,
18.0 g, 105.5 mmol) in the presence of 1-ethyl-3-(dimethylamino-
propyl) carbodiimide hydrochloride (EDC, 4.0 g, 20 mmol) over-
night at a pH of 4.75. The hydrazide-modiﬁed hyaluronic acid (HA-
ADH) was puriﬁed with decreasing amounts of NaCl (100, 75, 50,
25 mmol) for 4 h each via dialysis (8000 MWCO). The solution wasthen puriﬁed via dialysis (8000 MWCO) in deionized water for 2
days and lyophilized. The HA-ADH was re-suspended in 4-(2-
hydroxyethyl)-1-piperazine ethane-sulfonic acid (HEPES) buffer
(10 mM HEPES, 150 mM NaCl, 10 mM EDTA, pH 7.4) and reacted
with N-acryloxysuccinimide (NHS-AC), 1.33 g, 4.4 mmol overnight.
After puriﬁcation via dialysis as described earlier, the acrylated HA
(HA-AC) was lyophilized. The product was analyzed with 1H NMR
(D2O) and the degree of acrylation (14.9%) determined by dividing
the multiplet peak at d ¼ 6.2 (cis and trans acrylate hydrogens) by
the singlet peak at d ¼ 1.6 (singlet peak of acetyl methyl protons in
HA). This gel was chosen because of its biocompatibility with hu-
man tissue, as it is constituted of naturally occurring brain extra-
cellular matrix constituents. The mechanical properties of this gel
are similar to those of normal brain. HA has been shown to promote
angiognesis in a mouse model of skinwound healing [21,22]. Biotin
was then introduced to HA-AC using sulfo-NHSeLCebiotin
(NHSebiotin). NHSebiotin (100 mg) was added as a solid to a so-
lution of HAeAC (300 mg; 3 mg/mL in PBS; pH 7.4) as previously
described [22]. The reaction proceeded for 16 h at room tempera-
ture with stirring. The reaction product was then puriﬁed by dial-
ysis (MWCO 14,000) against distilled water for 24 h. The ﬁnal
puriﬁed product was lyophilized and stored at 4 C until used.
2.3. Heparin modiﬁcation
Heparin Carboxylic acid groups (Alfa Caesar, Ward Hill, MA)
were functionalized with thiol groups by dissolving 2 mg/mL of
heparin in PBS. To this solution, EDC, NHS, and an excess amount of
cysteamine were added. The pH of the reaction mixture was
adjusted to 4.75 and the reaction was allowed to continue over-
night with stirring at room temperature. DTT was then added to
reduce the oxidized disulﬁde groups in order to release thiol
groups. This solution was allowed to react overnight at pH 7.5 and
then adjusted to pH 3.5 by the addition of 1.0 N HCl. Next, the re-
action solution was dialyzed and lyophilized. The amount of the
thiol group attached to heparin was measured using the molar
absorptivity of Ellman's reagent at 412 nm.
2.4. Gelation
Lyophilized acryl hydrazide hyaluronic acid was dissolved in 4-
(2-hydroxyethyl)-1- piperazine ethane-sulfonic acid (HEPES, 0.3M)
buffer for 15min at 37 C for the in vitro experiments, and 20min at
room temperature for the in vivo injections. The appropriate con-
centration of Ac-GCGYGRGDSPG-NH2 adhesion peptide (RGD,
Genscript, Piscataway, NJ), Ac-GCGYGYIGSR-NH2 (YIGSR, Gen-
script), Ac-IKVAVGYGCG-NH2 (IKVAV, Genscript) was dissolved in
0.3 M HEPES and added to the dissolved HA-AC and allowed to
react for 20 min. For in vitro studies gel culture media, iPS-NPCs
(3000 cells/mL ﬁnal concentration), were then added. Heparin and
growth factors were then added to the gel precursor solution,
before the addition of a MMP-degradable peptide cross-linker (Ac-
GCRDGPQGIWGQDRCG-NH2, Genscript), dissolved in 0.3 M HEPES.
For in the in vitro experiments, 5 mL of this solution was pipetted
onto, and sandwiched between two Sigmacote (Sigma-Aldrich)
functionalized glass coverslips and placed in an incubator for
30 min at 37 C to gel. For injections into stroke brains, the pre-
cursor was loaded into the Hamilton syringe directly aftermixing in
the desired cross-linking peptide. The gel remains liquid for at least
10 min after mixing, allowing it to be injected.
2.5. Rheometry
Gels without cells were made as described above and cut to size
using a 8.0 mm biopsy punch. The modulus was measured with a
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VA) using a 8 mm plate with a frequency range of 0.1e10 rad/s
under a constant strain of 1% at 37 C. An evaporation blocker
system was used to keep the gel from dehydrating during the test.
Addition of iPS-NPCs to the HA gel did not change mechanical
properties of gels shortly after gelation (Fig. 1 [54]).
2.6. Cell survival in vitro
Cell survival wasmeasured using the CyQUANTcell proliferation
assay kit (Invitrogen). Gels werewashed twice in 1 PBS and frozen
in a80 freezer at days 1 and 7 after gel gelation. After thawing the
gels at room temperature, they were degraded by incubation in
TrypLE express (Invitrogen) at 37 C for 15 min. The cells were
isolated by centrifuging the solution at 250 g for 5 min and re-
suspended in 200 mL of the CyQUANT GR dye/cell-lysis buffer. Af-
ter 5 min incubation, the ﬂuorescence was read using a plate reader
at 480 nm.
2.7. Flow cytometry
Gels at day 1 or 7 after gelation were rinsed in 1 PBS and
degraded by pipetting the gel up and down via a 1000 mL pipette.
The solution was spun at 250 g for 10 min and re-suspended in BD
Cytoﬁx (Becton Dickinson, New Jersy) for 30 min at room temper-
ature. After spinning down at 250 g for 5 min, samples were re-
suspended in 1 PBS þ1% bovine serum albumin (BSA, Fisher
Scientiﬁc) þ 0.2% saponin (Sigma-Aldrich) for 15 min at room
temperature. Antibodies were then added to the solution for
30 min at room temperature. Following a spin at 250 g for 5 min,
the samples were re-suspended in 1% paraformaldehyde for Fluo-
rescence Activated Cell Sorting (FACS). Analysis was performed
using a FACScan X (BD Bioscience, San Jose, CA) and the data was
analyzed using FLOWJO (Version 10.0.7; Tree Star Inc, Ashland, OR).
Triplicates were done for each condition with 3000 events/sample.
The Dcx samples were gated to contain the positive signal peak.
2.8. Design of experiments
JMP software (SAS, Cary, NC) was used to generate the gel
conditions and to analyze the subsequent data. A surface response
methodology (RSM) setup was used to vary the ligands of interest
within a speciﬁc concentration range using a central composite
inscribed design (CCI). For each iteration, a response surface
methodology experiment was developed in which each variable
factor was given a deﬁned range (mM) to be modulated within.
Here, the Central composite on face, a speciﬁc RSM statistical
design was chosen, as this system enabled us to test the end points
of each factor. Data from the cell survival assay for each condition
recommended was inputted back into the software. The data was
analyzed via a least squares regression model to determine signif-
icance of the factors and plot the predicted response surface. Each
condition was done in triplicate and data from gels at day 7 were
normalized to gels from the same condition at day 1 to account for
any differences in the numbers of cells encapsulated in the gel
precursor solution.
2.9. Inducing stroke and transplantation
The procedures involving animals and human cells were per-
formed in accordance with National Institutes of Health Animal
Protection Guidelines and approved by the UCLA Chancellor's An-
imal Research Committee as well as the UCLA Ofﬁce of Environ-
ment Health and Safety. A cortical model of photothrombotic stroke
was produced in 2-month-old male C57BL/6 (Jackson Laboratory,Bar Harbor, ME) or Nod-Scid-gamma (NSG) mice (Jackson Labora-
tories). Mice were anesthetized and maintained with 2% isoﬂurane
in N2O:O2 (2:1). Strokewas producedwith a light-sensitive dye in a
photothrombotic approach as previously described [23]. Brieﬂy,
mice were positioned in a stereotaxic instrument and administered
Rose Bengal (10 mL/gr from 10 mg/mL solution, i.p.). A 2 mm
diameter region of the closed skull was illuminated with a white
light for 15 min. Temperature was maintained at 37 ± 0.5 C
(RightTemp™, Kent Scientiﬁc, Torrington, CT). The mouse was
allowed to recover in its home cage. Seven days after stroke, when
the necrosis of infarcted tissue at the stroke core has made a po-
tential space for incorporating injected volumes [24], cells, gel or
cells encapsulated in gel were injected into the core of stroke. Cells
were spun at 300 g for 5 min and re-suspended in PBS or HA gel
premix (including gel ingredients without cross-linker) at
50,000 cells/mL (or 25,000 cells/mL for the experiment studying
effects of cell concentration on HA gel resorption). To inject cells
encapsulated in gels or gels alone the cross-linker was added and
thoroughly mixed immediately before the gel mixture was with-
drawn into a 25 mL Hamilton syringe (Hamilton Company, Reno,
NV). Injections were conducted through a 30 G Hamilton needle
into a point 0.6 mm below the surface of the brain. Two mL of
volume, was injected at 0.3 mL/mL rate. To study cell survival in
C57BL/6 mice, animals were immunosuppressed with Tacrolimus
(Cell Signaling, Danvers, MA). Four intraperitoneal injections of
Tacrolimus (3mg/kg; dissolved in DMSO) were delivered for total of
4 days starting 2 days before implanting minipumps. At the time of
the stroke surgery, 3 mg/kg/day Tacrolimus (dissolved in 50%
DMSO, 15% ethanol and 35% distilled water) was infused from a
minipump (Model 1002; DURECT Corporation, Cupertico, CA).
Minipumps were implanted subdermally between the scapulae
and changed every two weeks. Upon minipump extraction a suc-
cessful infusion of Tacrolimus was ensured by checking for any
remaining Tacrolimus solution. Additional subcutaneous injections
of tacrolimus were administered on the day of pump replacement
since it takes ~12 h for miniosmotic pump to start infusion.
2.10. Magnetic resonance imaging of mice
Mice were anesthetized and placed in a small animal MRI (7T,
Bruker BioSpin, Fremont, CA) 9 weeks after stroke. Respiratory rate
was monitored throughout the procedure and body temperature
was maintained at 37 ± 0.5 C. A T2-weighted image set was ac-
quired with the following parameters: rapid acquisition relaxation
enhancement factor 8, repetition time 5300ms, echo time 15.00ms
with an in-plane resolution of 0.039_0.039_0.50 mm with 13
contiguous slices. The MRI images were exported by the software
ParaVision 5.1 (Bruker BioSpin, Fremont, CA) into a high-resolution
ﬁle format (2DSEQ) and volumetric measurements were performed
in ImageJ (National Institute of Health, Bethesda, MD). Gel area,
which was represented as a T2 hyperintense signal in T2 sequence
images, was quantiﬁed in all MRI images cut through lesion areas.
2.11. Tissue processing
Infarct size was determined 3e5 days after stroke by staining
with a 2% triphenyl tetrazolium chloride (TTC; gr/mL, made in PBS;
Sigma-Aldrich, St Louis, MO) solution for 40 min at 37 C. The brain
was then cut in 1 mm sections using a mouse Brain Matrix (Zivic
Instruments, Pittsburgh, PA) and imaged using a stereomicroscope.
The same preparation was used to quantify hydrogel volume one
day after injection. For immunohistochemical studies mice were
euthanized at 2 weeks or 6 weeks after cell or gels or cells in gels
injections and perfused with 4% paraformaldehyde (Fisher Scien-
tiﬁc, Pittsburgh, PA; in PBS, pH: 7.4) and cryoprotected in sucrose
Fig. 1. Mechanical and composition gel optimization (A) Schematic illustration of the injectable hyaluronic acid (HA) composed of acrylated hyaluronic acid, MMP degradable or
non-degradable motifs, adhesion peptides and heparin bound growth factors. (B) Characterization of stiffness and crosslinker. (Bi) Schematic illustration of brain coronal sections
and their orientations. The stroke cavity is represented by the asterisk. (Bii, Biii) TTC-stained brain sections showing infarcted tissue (delimitated by dotted line) without (Bii) and
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mounted on gelatin-coated Superfrost® slides (Fisher Scientiﬁc).
2.12. Immunohistochemistry
For transplant cell quantiﬁcation, tissue sections were stained
for HuNu, a human-speciﬁc nuclear antigen, using avidin-biotin
complex (ABC) ampliﬁcation (VECTASTAIN® Elite® ABC Kit-Mouse
IgG, Vector Laboratories, Burlingame, CA) and 3,3’-dia-
minobenzidine (DAB) labeling (ImmPACT™ DAB, Vector Labora-
tories) with blocking of endogenous biotin (Lab Vision™, Thermo
Fisher Scientiﬁc, Fremont, CA). Immunoﬂuorescence was per-
formed using primary antibodies (Table S1) incubated overnight.
HA gels were labeled for the biotin, and this was visualized using
streptavidin tyramide signal ampliﬁcation (TSA™, Life Technolo-
gies). All antibodies utilized are in Supplementary Table [54].
2.13. Tissue analysis
Stroke volume was quantiﬁed in TTC-stained 1 mm brain sec-
tions by summing stroke areas multiplied by inter-slice distance of
1 mm. To measure vessel density inside transplants, slides were
scanned with laser scanning confocal microscopy (C2 Series, Nikon
Instruments Inc., Melville, NY), total length of vessels was
measured by ImageJ and divided by volume of transplant computed
as area multiplied by the section thickness. For colocalization
studies the percentage of tissue volume in which GFP marker
colocalized with a second marker was calculated in confocal image
stacks using IMARIS software (Bitplane, South Windsor, CT).
2.14. Statistics
Tests were analyzed blindly to experimental condition. Animals
were randomly assigned to control and treatment groups. Power
analysis tool (Statistical Solutions LLC, Cottage Grove, WI) was
employed to calculate sample size with the expected variance and
changes in predicted proliferation and differentiation rates based
on preliminary data. Data for each group/time-point comprise 4e7
individual animals. Data is presented as mean ± SEM. Multiple
comparisons ANOVA with Bonferonni or Dunnet (when compared
against control) post-hoc tests were performed on data. If data did
not ﬁt into a normal distribution then tests appropriate for non-
parametric variables, such as Mann-Whitney test (for comparison
between two groups) or Kruskal-Wallis test (for comparison among
three or more groups) followed by Dunn post-hoc test, were
employed.
3. Results
3.1. Optimizing mechanical properties of HA gel in vivo
With the goal of injecting this gel into the stroke cavity, we
identiﬁed the mechanical properties and gelation conditions that
allowed the gel to fully ﬂow into and ﬁll the stroke cavity before
gelation. HA gels with three different stiffness levels 100, 350 and
1000 Pa were injected in the stroke cavity (Figure 1A, 1Bi-iii) onewith (Biii) injection of a 350 Pa gel in the stroke cavity. (Biv, Bv) Vascular laminin staining (gre
or sensitive (or MMP-Sen; Bv) cross-linker. (Bvi) Quantiﬁcation of gel volume, (Bvii) infar
optimize concentrations of (C) soluble or (D) bound growth factors. iPS-NPCs survival in HA g
factors. DOE prediction for the maximized and minimized cell proliferation for (Cii) soluble a
iPS-NPCs survival, (Eii) sprouting (Dcx staining) and (Eiii, Eiv) differentiation (% of Dcx cells
Schematics of the ﬁnal optimized condition for in vivo testing and table of the gel compon
trations of adhesion motifs and no GFs. Scale bars represent 1 mm (Bii, Biii), 100 mm (Biv, Bv)
interpretation of the references to colour in this ﬁgure legend, the reader is referred to theweek after the stroke onset. This time point of injectionwas chosen
as it corresponds to a period in which cell death in stroke is com-
plete, and a clinical window inwhich patients might receive a stem
cell/hydrogel therapy [2]. Twenty-four hours after the injection,
both the intracerebral volume of gel and the remaining damaged
tissue in the stroke area were measured. Both the 350 Pa and 1 kPa
HA gels had signiﬁcantly more volume of gel remaining in the brain
(Fig. 1Bvi). However, the injected 350 Pa gel, which matches the
mechanical properties of brain cortex [25], was associated with the
lowest remaining volume of infarcted tissue (Fig. 1Bvii), thus
occupying the stroke cavity with the highest efﬁciency and estab-
lishing the most optimum gel-tissue interface. This greater
expansion of the 350Pa gel and more complete occupation of the
stroke cavity could be described because this gel matches the brain
tissue's stiffness and leads to the gel conforming to stroke cavity
boundaries and expelling, or compressing infarcted tissue. There-
fore, the 350 Pa gel was chosen for the rest of the study.
3.2. Crosslinker sensitivity to MMPs in vivo
Hydrogel cross-linkers inﬂuence gel stability and degradation
processes [26]. Stroke induces degradative enzyme, such as matrix
metalloproteinaes (MMPs) [25], that may serve to modify an
injected hydrogel. Crosslinking motifs sensitive to MMPs were
incorporated in the gel and compared to the hydrogel cross-linked
with motifs insensitive to the enzymes. Two weeks after gel in-
jection, mice were sacriﬁced and brain sections were stained for
collagen (Fig. 1Biv, v), a component of the vascular basement
membrane [27]. While very few vessels were found in the MMP-
insensitive condition (Fig. 1Biv), a signiﬁcantly increased vascular
in-growth was observed in the MMP-degradable gel (Fig. 1Bv, viii).
3.3. DOE approach to optimize the concentration of adhesion motifs
and growth factors in vitro
Incorporating biochemical cues within hydrogel materials used
for stem cell transplantation is an ideal approach to control survival
and differentiation. However, there is a disconnect between the
studies performed in vitro, which often utilize soluble differentia-
tion cocktails to achieve differentiation, and the gels that are used
in vivo. This is because either the precise control over an in vitro
biochemical environment is not plausible in vivo, or a different
in vivo differentiation outcome is observed despite of delivering the
same in vitro growth factor cocktail. Our group recently showed
that a statistical Design of Experiment (DOE) approach [21] can be
used to optimize the concentration of adhesionmotifs derived from
laminin (IKVAV and YIGSR) and ﬁbronectin (RGD) to promote the
in vitro survival of iPS-NPCs and demonstrated that the optimal
condition promoted neuronal differentiation [13]. Here we utilize
the same DOE approach to optimize the concentration of brain-
derived neurotrophic factor (BDNF) and bone morphogenic
protein-4 (BMP-4) (both of which have potent effects on NPC dif-
ferentiation [28]) to promote survival in vitro and differentiation to
different lineages in vivo. Human iPS-NPCs were used in these
studies as these are a viable therapeutic candidate for a stem cell
therapy in stroke [29].en) in HA gel (red) at 2 weeks post-injection with an MMP insensitive (or MMP-In; Biv)
cted tissue and (Bviii) the vascular density in the injected HA gels. DOE approach to
el at 1 week in response to varying concentrations of (Ci) soluble or (Di) bound growth
nd (Dii) bound growth factors. (E) Combining optimal growth factor concentrations. (Ei)
by ﬂow cytometry) in the combined optimization HA Max and HA Min at 1 week. (F)
ent concentration. HA Nopt demonstrates non-optimized gel with equimolar concen-
and 50 mm (Eiv). *, ** and *** indicate P < 0.05, P < 0.01 and P < 0.001, respectively. (For
web version of this article.)
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hydrogel matrix in vivo, heparin was introduced to the HA back-
bone. Two separate DOE optimizations were performed using sol-
uble or heparin-bound growth factors. For each DOE optimization
experiment 5 different concentrations of BDNF or BMP-4 (0, 50,
100, 150 or 200 ng/mL) were combined into twelve different gel
conditions (Fig. 1Ci and 1Di) while keeping one single peptide motif
(RGD: 300 mM) constant. The soluble forms of BDNF and BMP-4
resulted in an optimal combination for the greatest (BDNF:
200 ng/mL, BMP-4: 0) and least cell survival (BDNF: 0 ng/mL, BMP-
4: 26.52 ng/mL; Fig. 1Cii). As expected the bound forms of growth
factors (GF) resulted in a different optimal formulation for the
greatest survival labeled as “GF Max” (BMP-4: 37.22 ng/mL; BDNF:
0 ng/mL) and the least survival labeled as “GF Min” (BDNF: 200 ng/
mL; BMP-4: 155.28 ng/mL, Fig. 1Dii). Differences between soluble
and bound growth factors have been previously observed and can
be attributed to different signaling responses for bound growth
factors [30]. All conditions had a cell survival equal to or greater
than the cell number found at day 1 after iPS-NPC encapsulation
within the hydrogels.
This approach optimized growth factors and adhesion peptides
separately. A ﬁnal stage of optimization consisted of combining
both optimal formulations for growth factors (“GF Max”, “GF Min”)
and the optimal regimen for peptides (“Pept Max”: RGD: 100 mM,
IKVAV: 48 mM, YIGSR: 300 mM and “Pept Min”: RGD: 0, IKVAV:
100 mM, YIGSR: 45 mM from Ref. [21]) described as GF Max þ Pept
Max¼HAMax, and GFMinþ Pept Min¼HAMin (Fig. 1F). HA Nopt
gel remained as a non-optimized interim control gel with equi-
molar concentrations of adhesion motifs and no GF. These condi-
tions proposed by DOE were then tested in vitro to conﬁrm the
effects on survival, spreading and differentiation of encapsulated
iPS-NPCs using immunoﬂuorescence staining and ﬂow cytometry
(Fig. 1Ei-iv). HA Max, the gel optimized by DOE to promote cell
survival, was associated with signiﬁcantly increased cell survival,
axonal sprouting, and expression of a neuronal differentiation
marker, doublecortin (Dcx) [31] compared with HA Min and a non-
optimized control gel with only RGD motif. Interestingly the HA
Min condition, designed to lower cell survival in DOE approach,
showed a statistically lower cell survival and differentiation than
the RGD only control gel and the GF Min condition, respectively
(Fig. 1Ei, iii). Therefore the HA gel formulations predicted by DOE
approach showed consistent in vitro results.
3.4. Effects of gel composition on brain tissue adjacent to the stroke
This step-by-step hydrogel optimization led to four candidates
for in vivo testing: 1) an empty HA gel without any adhesion peptide
or growth factor (HA), 2) a non-optimized gel with equimolar
concentrations of RGD, IKVAV and YIGSR peptides (100 mM each)
and no growth factors as a control for DOE optimization process
(HA Nopt), 3) a gel with both optimized concentrations of growth
factors and of peptides for a maximum cell survival in vitro (HA
Max) and 4) a comparator gel with the same growth factors and
adhesion motifs but with concentrations to result in a minimized
cell survival in vitro (HA Min). A ﬁrst in vivo experiment aimed at
evaluating the effect of the different gel conditions in the absence of
encapsulated cells on the activation of host tissue microglia and
astrocytes, as HA hydrogels may induce an inﬂammatory and
astrocytic reaction to an injected scaffold [15]. C57BL/6 mice were
injected with the four different gel conditions directly into the
stroke cavity one week after the stroke onset and sacriﬁced two
weeks later. Brain sections were stained for GFAP (astrocytes) and
Iba1 (microglia) and compared with a non-injected stroke condi-
tion as a control. No signiﬁcant difference was observed among all
the conditions (Fig. 2 [54]), indicating that none of the HA groupsinduced a greater inﬂammatory or astrocytic response than the
stroke insult itself.
3.5. HA gel degradation and angiogenesis
Timely degradation of bioscaffolds is of paramount importance
in tissue engineering. To determine the contribution of trans-
planted iPS-NPCs vs. host tissue in degradation of HA gels over
time, the gel optimized for highest cell survival, spreading and
differentiation, HA Max, was chosen. The biotin-tagged gel was
loaded with either 50,000 or 100,000 iPS-NPCs prior to trans-
plantation into the stroke area of immunodeﬁcient NSG mice one
week after stroke. Two and six weeks later, the results showed that
the gel loaded with 100,000 cells lost substantial volume between
the two time points (Fig. 2A, B) while the gel loaded with
50,000 cells remained relatively intact for as long as six weeks
(Fig. 2C). The same observation was made with pharmacologically
immunosuppressed C57BL/6 mice to mimic cell therapy for stroke
in a clinical setting (data not shown). A T2 MRI sequence was used
in these mice to quantify the remaining gel volume at nine weeks
post-transplantation in vivo. HA hydrogels are visible on T2 MRI,
due to their hydration shortening the T2 relaxation time [3]. The
addition of 100,000 cells signiﬁcantly decreased the gel volume
compared with a cell-free gel (Fig. 2DeJ), suggesting that encap-
sulated cells, rather than the host brain tissue, are involved in the
hydrogel breakdown. This breakdown may also be through the of
inﬁltration adjacent brain tissue, such as the vasculature [15].
Fluorescent staining of vessels (CD31) revealed the presence of an
extended vascular network within the gel as early as 2 weeks post-
injection, displaying a close interactionwith encapsulated iPS-NPCs
(Fig. 2KeO). The same observation was made in the three other HA
conditions. No signiﬁcant difference in measured vascular density
was observed between gel transplant groups (data not shown).
3.6. Effects of HA gel composition on human iPS-NPC proliferation
and differentiation in vivo
To test the effect of the four distinct gels on iPS-NPC prolifera-
tion and differentiation after stroke, iPS-NPCs were transplanted
into the stroke cavity of immunodeﬁcient NSG mice 7 days after
stroke. The NSGmouse strainwas chosen to minimize the effects of
host inﬂammation on in vivo cell proliferation and differentiation,
as well as cell-scaffold interactions. Brain sections were stained for
human nuclear antigen (HuNu) and the proliferation marker
Ki67 at two and six weeks after transplantation, and double posi-
tive cells were counted (Fig. 3A,B). The HA Max condition was
associated with a signiﬁcantly increased proliferation at twoweeks
compared with all the other conditions, before this level of prolif-
eration decreased, showing no signiﬁcant difference at the six week
time point across gel transplant groups. Interestingly the six week
time point coincides with gel degradation (Fig. 2B) that would
naturally terminate the pro-survival effect of HA Max gel on
encapsulated cells.
iPS-NPC differentiation was studied by co-staining cells with
SOX2 and NF200, expressed by immature neural precursors [32]
and neurons [33], respectively. Notably all iPS-NPCs express SOX2
upon differentiation from iPS cells in vitro (data not shown),
consistent with its known role in neural precursor function [19].
Non-encapsulated cells (No HA condition) were found to retain
signiﬁcantly higher levels of SOX2 expression compared to the
conditions in which iPS-NPCs were transplanted within a hydrogel
(Fig. 3B) In addition iPS-NPCs transplanted in HA Nopt gel had a
signiﬁcantly increased co-labeling with NF200 compared with
other groups, indicating a neuronal phenotype. In all transplant
conditions iPS-NPCs did not express Oct4, a marker of stem cell
Fig. 2. Biomaterial inﬁltration and resorption in vivo. Fluorescent image of stroke area (A) 2 weeks and (B) 6 weeks after transplantation with 100,000 iPS-NPCs (green)
encapsulated in HA Max (blue), or (C) 6 weeks after transplantation of 50,000 iPS-NPCs encapsulated in HA Max. (D) Brain MRI images of animals at 9 weeks after stroke (dashed
rectangle), (E) stroke plus HA Max injection and (F) stroke plus transplantation of 100,000 cells encapsulated in HA Max. (J) Quantiﬁcation of gel representing T2 signal (arrowhead
in E and F). (K) Fluorescent staining of vascular growth within HA Max at two weeks after transplantation, where the area demarcated in dashed line is magniﬁed in L (merged), M
(transplanted cells, in green), N (CD31 positive endothelial cells, in red) and O (gel, in blue). Scale bar represents 100 mm (AeC) and 10 mm (KeH). ** indicates P < 0.01. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
P. Moshayedi et al. / Biomaterials 105 (2016) 145e155 151pluripotency, indicating that there was not a de-differentiation
across groups (data not shown). These ﬁndings indicate that
encapsulation in any type of HA gel promotes differentiation away
from the progenitor state after transplantation and this differenti-
ation can be further directed towards neuronal cells with equimolar
concentration of adhesive peptides in the absence of growth fac-
tors. Interestingly, the HA Max did not promote neuronal differ-
entiation (Fig. 3A, B) even though it contains BDNF [34] and BMP4
[35], growth factors that are associated with neuronal differentia-
tion. This ﬁnding indicates that in vivo differentiation is more
complex and multifactorial than expected.To further study the effect of HA gels on glial differentiation as
an alternative to neuronal differentiation of iPS-NPCs, tissue sec-
tions were stained for GFAP, expressed by both immature and
mature astrocytes as well as NPCs, and S100b, mainly expressed by
mature astrocytes [36] (Fig. 4A). The ratio of GFP cells expressing
only GFAP or both GFAP and S100b was quantiﬁed (Fig. 4B). iPS-
NPCs encapsulated in HA Max gels had a signiﬁcantly increased
expression of both GFAP and S100b markers compared with the
other groups. In our experimental paradigm S100b staining is more
conﬁned to astrocyte identity in contrast to GFAP staining, associ-
ated with both astrocytes and also reported in NPCs. To distinguish
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state, the ratio of GFP-GFAP-S100b over GFP-GFAP revealed that the
majority of GFP cells expressing GFAP also express S100b. This
conﬁrms that encapsulation in HA Max gels promotes astrocytic
differentiation of iPS-NPCs within the stroke cavity.
3.7. Effects of HA gels on cell survival in vivo
Previous studies have indicated poor cell survival when directly
injected into or near the stroke cavity [37]. Yet, the stroke cavity is
an attractive clinical transplant site because it is a cavity and can
accept a large volume injection [3] and because it is directly adja-
cent to the site of the most substantial plasticity and recovery after
stroke, the peri-infarct tissue [38]. In the preceding experiments,NSG mice were used so that prolonged immunosuppressive regi-
mens would not be necessary and the focus would be on the
hydrogel effects on transplant cell differentiation. However, the
deﬁcient immune system of NSG mice allowed iPS-NPC survival
equally in encapsulated and non-encapsulated cells (Figs. 3A and
4A, also quantiﬁed cell number; data not shown) likely because
the inﬂammatory insult on transplanted cells was too weak to
require protective effects of growth factors and adhesion motifs on
graft survival. To study pro-survival effects of HA gels in a condition
mimicking clinical situations we used single agent immunosup-
pression, an approach used in human stem cell transplant trials
[39], in C57Bl/6 wild type mice. Using GFP ﬂuorescence quantiﬁ-
cation we found that encapsulating iPS-NPC in HA Max gel pro-
moted survival two weeks after transplantation into the stroke
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low numbers (Fig. 3C). This indicates that in addition to controlling
cell differentiation, HA gels promote survival in the early period
after transplant.4. Discussion
HA hydrogels promote differential maturation of neural pro-
genitors in vivo within the stroke cavity, enhance survival of
transplanted cells and represent a therapeutic approach that can be
tracked in vivowith MRI. When directly injected into stroke (No HA
condition) most iPS-NPCs retained SOX2 expression, a marker of
immature neural progenitor cells [32]. iPS-NPCs preferentially
differentiated into neurons when theywere transplanted within an
HA gel that contained ﬁbronectin and laminin peptide motifs in
maximal concentrations (HA Nopt). An HA gel with peptide motifs
and BMP4 and BDNF growth factors optimized in vitro for survival
and proliferation promoted astrocytic differentiation in vivo. Both
astrocyte and neuronal differentiation of transplanted neural pro-
genitor cells has been suggested as a potential therapy in brain
diseases [29] indicating that modulation of progenitor cell differ-
entiation toward either lineage may have clinical utility. This is theﬁrst report of selective control of neural progenitor cell differenti-
ation in vivo after transplantation in stroke. These studies indicate
that hydrogel scaffolds can be used to tune the differentiation of
early progenitor cells toward distinct cell types, and provide ﬂex-
ible derivation of a particular neural repair therapy within the brain
itself. Furthermore, this hydrogel scaffold/stem cell transplant
approach promotes transplant survival within the stroke cavity, an
avascular and inﬂamed tissue environment that is nonetheless a
good site for a transplant therapy.
This study brings a deeper understanding of the environmental
cues that dictate neural progenitor differentiation into specialized
cells. All HA conditions were associated with cell differentiation to
some extent, implying that the presence of the polymer scaffold
itself guided cell exit from the multipotent progenitor stage inde-
pendently of the addition of extracellular matrix cues or trophic
factors. A second level of cell signaling further specifying a differ-
entiation route is then seen in the unique cell fate associated with
each HA condition, indicating that if the scaffold does not selec-
tively engage a speciﬁc pathway, the gel composition does, high-
lighting the importance of the choice and combination of these
cues and growth factors to optimize the hydrogel for the desired
effect. Here, a non-optimized hydrogel (HA Nopt) characterized by
P. Moshayedi et al. / Biomaterials 105 (2016) 145e155154an equimolar concentration of adhesion peptides promoted the
formation of neurons, while an optimized gel for a maximized
in vitro survival (HA Max) induced the in vivo state an early pro-
liferation and formation of astrocytes. In a similar observation the
pro-survival effect, an HA-methylcellulose-based hydrogel was
coupled with differentiation of human oligodendrocyte progenitor
cells towards astrocytic phenotypes following transplantation into
spinal cord injury [40]. Interestingly, the gel that produced mini-
mized in vitro survival (HA Min) minimized neuronal differentia-
tion in vivo. These results suggest that altering NPC proliferation
and survival prevents cells from completing their differentiation to
neurons.
Engineering a 3D biomaterial to culture and transplant cells
enabled us to create a complex matrix environment by keeping the
hydrogel platform and cell type constant across conditions while
systematically varying peptide motifs and growth factors, high-
lighting the tunable characteristics of bioengineered synthetic
matrices. Since advances have been made to improve the trophic
abilities of engineered hydrogels to promote brain tissue regener-
ation, many recent combinatorial strategies have demonstrated the
synergistic beneﬁts of combining stem/progenitor cells and matrix
[6,41]. However, the majority of these studies have attempted to
maximize the beneﬁt of combination therapies by either changing
one unique aspect of the therapy while maintaining the other el-
ements constant [42,43], by using a “presence/absence” binary
evaluation of the matrix component [8,44], or by picking random
concentrations (usually equimolar) for all the factors tested [42,45].
The use of DOE allows systematic alteration of multiple compo-
nents of the hydrogel to determine outcome characteristics for
further in vivo testing.
Tissue engineering in regenerative medicine requires over-
coming complex control issues on two levels. The transplant itself
exhibits a complex interaction with the recipient tissue and with
adjoining transplant cells. Second, the recipient tissue has a com-
plex structure and cell composition that makes tissue replacement
challenging. Recently, studies have addressed transplant survival
along with differentiation and repair of the recipient tissue with a
data-driven statistical approach to optimize the gel composition to
promote tissue repair. Many of these investigations have transi-
tioned from in vitro to in vivo in the tissue-engineering ﬁeld of or-
gans such as retina [46], skin [47], liver [48], digestive tract [49], ear
[50], pancreas [51], lungs [52] and skeletal muscle [53]. However
the systematic development of a bioengineered scaffold for the
brain with DOE studies has been rarely pursued past the in vitro
stage [21,22]. This work provides the ﬁrst evidence supporting the
multi-factorial cell/hydrogel/DOE approach that combines me-
chanical, biochemical and trophic factors to 1) systematically
modify multiple factors at the same time, 2) identify the speciﬁc
combination that promotes the desired cell behavior and 3) selec-
tively control the in vivo distinct cell fate of transplanted cells. This
works highlights the importance of interdisciplinary collaborations
between engineers, clinicians, and biologists in the development of
innovative cell transplantation therapies after stroke.
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